TCTR20210219004Unknown2 期
Acute skin toxicity and cosmesis outcome in ultrahypofractionated radiotherapy for non metastatic breast cancer treated with proton radiotherapy compared with photon radiotherapy
ational research and innovation information system0 个研究点目标入组 140 人开始时间: 2021年2月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 21 Years 至 99 Years（—）
- 性别
- Female
入选标准
- •Female who pathologically proven breast cancer and undergone surgery (mastectomy and breast conservation surgery).
- •Aged at least 21 year old
- •Stage 1-3 (according to AJCC 8th edition)
排除标准
- •Prior radiotherapy to ipsilateral breast/thorax/chest wall
- •Any radiotherapy for currently diagnosed breast cancer prior to randomization
- •Any active skin problem on chest wall and axillary area or connective tissue disease
- •Other non malignant system disease that would prevent patients from receiving study treatment or required follow up including pregnancy or lactating
- •Surgical margin positive
- •Bilateral breast cancer
研究者
相似试验
已完成
2 期
Effect of boost technique on toxicity of breast cancer radiotherapyBreast cancer.Malignant neoplasms of breastIRCT20220221054089N1Tehran University of Medical Sciences100
尚未招募
不适用
Incidence of cutaneous complications in advanced solid cancer patient treated with epidermal growth factor receptor inhibitorsadvanced solid cancer patientsepidermal growth factor receptor inhibitorsacneiform eruptionparonychiahair abnormalitiesskin drynesspruritusEGFR inhibitorsradiotherapyconventional chemotherapyacneiform eruptionhair abnormalitiesskin drynesspruritusparonychiaTCTR20170727001Quality Improvement Fund, King Chulalongkorn Memorial Hospital110
已完成
不适用
Evaluation of dermatological safety and adverse reaction of Tactivin Immunoplus (Immunomodulator) cream, Tactivin Anti Wrinkle cream and Tomicid (Antibacterial peptide) cream along with their Placebo with a 48 hours closed patch skin sensitization test on 24 healthy adult volunteersCTRI/2011/11/002112Remedia Therapeutics Pvt Ltd24
招募中
不适用
Safety testing of cosmetic product using Patch TestCTRI/2021/07/035262Entice Supplements Pvt Ltd
尚未招募
不适用
Rate of severe cutaneous adverse reactions due to first line Anti-tuberculosis drugs, Health Product Vigilance Center database; Food and Drug Administration, Ministry of Public Healthsevere cutaneous adverse reactionsSCARscutaneous adversed reactionsantituberculosisfirst line antituberculosis drugsSJSTENDRESSAGEPsevere cutaneous adverse reactionsSCARscutaneous adversed reactionsantituberculosisfirst line antituberculosis drugsDRESSAGEPSJSTENTCTR20180812003Tipsiri Chaikong3,500